
1. Lancet Infect Dis. 2021 Nov;21(11):1492-1493. doi: 10.1016/S1473-3099(21)00631-9.

Adverse event reporting and Bell's palsy risk after COVID-19 vaccination -
Authors' reply.

Wong ICK(1), Wan EYF(2), Chui CSL(3), Li X(4), Chan EWY(5).

Author information: 
(1)Centre for Safe Medication Practice and Research, Department of Pharmacology
and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
SAR, China; Laboratory of Data Discovery for Health (D24H), Hong Kong Science and
Technology Park, Sha Tin, Hong Kong SAR, China; Expert Committee on Clinical
Events Assessment Following COVID-19 Immunization, Department of Health,
Government of the Hong Kong SAR, Hong Kong SAR, China; Research Department of
Practice and Policy, School of Pharmacy, University College London, London, UK.
Electronic address: wongick@hku.hk.
(2)Centre for Safe Medication Practice and Research, Department of Pharmacology
and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
SAR, China; Department of Family Medicine and Primary Care, Li Ka Shing Faculty
of Medicine, University of Hong Kong, Hong Kong SAR, China; Laboratory of Data
Discovery for Health (D24H), Hong Kong Science and Technology Park, Sha Tin, Hong
Kong SAR, China.
(3)School of Nursing, Li Ka Shing Faculty of Medicine, University of Hong Kong,
Hong Kong SAR, China; School of Public Health, Li Ka Shing Faculty of Medicine,
University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for
Health (D24H), Hong Kong Science and Technology Park, Sha Tin, Hong Kong SAR,
China.
(4)Centre for Safe Medication Practice and Research, Department of Pharmacology
and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
SAR, China; Department of Medicine, Li Ka Shing Faculty of Medicine, University
of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health
(D24H), Hong Kong Science and Technology Park, Sha Tin, Hong Kong SAR, China.
(5)Centre for Safe Medication Practice and Research, Department of Pharmacology
and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
SAR, China; Laboratory of Data Discovery for Health (D24H), Hong Kong Science and
Technology Park, Sha Tin, Hong Kong SAR, China.

Comment on
    Lancet Infect Dis. 2021 Aug 16;:null.
    Lancet Infect Dis. 2021 Nov;21(11):1490-1491.
    Lancet Infect Dis. 2021 Nov;21(11):1491-1492.

DOI: 10.1016/S1473-3099(21)00631-9 
PMCID: PMC8550904
PMID: 34717806  [Indexed for MEDLINE]

Conflict of interest statement: ICKW reports research funding from Amgen, Bristol
Myers Squibb, Pfizer, Janssen, Bayer, GlaxoSmithKline, Novartis, the Hong Kong
Research Grants Council, the Hong Kong Health and Medical Research Fund, the
National Institute for Health Research in England, European Commission, and the
National Health and Medical Research Council in Australia. ICKW also reports
receiving speakers fees from Janssen and Medice, outside the submitted work. ICKW
is also an independent non-executive director of Jacobson Medical in Hong Kong.
EYFW has received research grants from the Food and Health Bureau of the
Government of the Hong Kong Special Administrative Region (SAR), and the Hong
Kong Research Grants Council, outside the submitted work. CSLC has received
grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong
Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer,
IQVIA, and Amgen, and personal fees from Primevigilance, outside the submitted
work. XL has received research grants from the Food and Health Bureau of the
Government of the Hong Kong SAR, research and educational grants from Janssen and
Pfizer, internal funding from the University of Hong Kong, and consultancy fees
from Merck Sharp & Dohme, outside the submitted work. EWYC reports honorarium
from Hospital Authority, grants from the Hong Kong Research Grants Council,
Research Fund Secretariat of the Food and Health Bureau, grants from National
Natural Science Fund of China, Wellcome Trust, Bayer, Bristol Myers Squibb,
Pfizer, Janssen, Amgen, Takeda, and the Narcotics Division of the Security Bureau
of the Hong Kong SAR, outside the submitted work.

